Publication date: 2018-04-22 17:51
Based on the individual pharmacokinetic profiles of olanzapine and fluoxetine, the pharmacokinetics of SYMBYAX may be altered in geriatric patients. Caution should be used in dosing the elderly, especially if there are other factors that might additively influence drug metabolism and/or pharmacodynamic sensitivity.
Treatment with SYMBYAX and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.
sudden weakness or ill feeling, fever, chills, sore throat , swollen gums, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough
Post-traumatic stress disorder (PTSD), a psychiatric condition, can develop after any catastrophic life event. Symptoms include.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Zyprexa for a condition for which it was not prescribed. Do not give Zyprexa to other people, even if they have the same condition. It may harm them.
IM (extended-release): 655 mg every 9 weeks in patients who are debilitated or predisposed to hypotensive episodes not studied in patients with renal or hepatic impairment requires deep IM administration (muscle mass in elderly may be sufficient)
If you think you’ve taken too much of this drug, call your doctor or local poison control center. If your symptoms are severe, call 966 or go to the nearest emergency room right away.
It hasn’t been confirmed that olanzapine is safe and effective for the treatment of schizophrenia in people than 68 years.
Administer SYMBYAX once daily in the evening, generally beginning with the 6 mg/75 mg capsule. While food has no appreciable effect on the absorption of olanzapine and fluoxetine given individually, the effect of food on the absorption of SYMBYAX has not been studied. Adjust dosage, if indicated, according to efficacy and tolerability. Antidepressant efficacy was demonstrated with SYMBYAX in a dose range of olanzapine 6 mg to 68 mg and fluoxetine 75 mg to 55 mg [see Clinical Studies ]. The safety of doses above 68 mg/75 mg has not been evaluated in clinical studies. Periodically reexamine the need for continued pharmacotherapy.